BioCryst Pharmaceuticals, Inc. $BCRX Shares Purchased by Inspire Investing LLC

Key Points

• Inspire Investing increased its BioCryst Pharmaceuticals stake by 426.1% in the third quarter, acquiring 293,899 additional shares for a total of 362,878 shares valued at approximately $3.0 million.
• Institutional investors and hedge funds own 85.88% of BCRX, with BlackRock, Jupiter Topco, Janus Henderson, Perceptive Advisors and Bank of America among other significant holders that recently increased or initiated positions.
• Analyst sentiment is mixed, with six Buy, four Hold and one Sell ratings, resulting in a consensus Hold rating and an average price target of $19.44. The stock recently opened at $7.65, while BioCryst’s latest quarterly results beat earnings and revenue expectations.

Inspire Investing LLC grew its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 426.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 362,878 shares of the biotechnology company's stock after buying an additional 293,899 shares during the period. Inspire Investing LLC owned 0.14% of BioCryst Pharmaceuticals worth $3,023,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in BioCryst Pharmaceuticals during the 2nd quarter worth $238,930,000. Jupiter Topco LLC purchased a new stake in BioCryst Pharmaceuticals in the 2nd quarter valued at approximately $95,268,000. Janus Henderson Group PLC boosted its stake in shares of BioCryst Pharmaceuticals by 20.3% during the 1st quarter. Janus Henderson Group PLC now owns 8,908,506 shares of the biotechnology company's stock worth $84,854,000 after purchasing an additional 1,504,120 shares during the last quarter. Perceptive Advisors LLC grew its stake in BioCryst Pharmaceuticals by 135.1% in the 1st quarter. Perceptive Advisors LLC now owns 7,434,033 shares of the biotechnology company's stock worth $70,772,000 after acquiring an additional 4,271,504 shares during the period. Finally, Bank of America Corp DE increased its stake in BioCryst Pharmaceuticals by 231.6% in the first quarter. Bank of America Corp DE now owns 5,091,765 shares of the biotechnology company's stock valued at $48,474,000 after purchasing an additional 3,556,208 shares during the last quarter. Institutional investors and hedge funds own 85.88% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on BCRX. Weiss Ratings downgraded shares of BioCryst Pharmaceuticals from a "hold (c)" rating to a "sell (d-)" rating in a research note on Tuesday, September 22nd. Wall Street Zen raised shares of BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Saturday. Wedbush lowered their price objective on shares of BioCryst Pharmaceuticals from $21.00 to $20.00 and set an "outperform" rating on the stock in a research report on Thursday, August 6th. JPMorgan Chase & Co. lifted their price objective on BioCryst Pharmaceuticals from $12.00 to $13.00 and gave the company a "neutral" rating in a research report on Wednesday, September 30th. Finally, Royal Bank Of Canada downgraded shares of BioCryst Pharmaceuticals from an "outperform" rating to a "sector perform" rating and cut their price target for the company from $13.00 to $11.00 in a report on Thursday, September 10th. Six investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $19.44.

BioCryst Pharmaceuticals Price Performance

BioCryst Pharmaceuticals stock opened at $7.65 on Friday. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $6.23 and a fifty-two week high of $11.22. The company's 50 day simple moving average is $8.79 and its 200 day simple moving average is $9.10. The firm has a market capitalization of $1.95 billion, a price-to-earnings ratio of -5.10 and a beta of 0.55.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.15 by $0.15. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The company had revenue of $218.25 million during the quarter, compared to analysts' expectations of $183.28 million. During the same quarter in the prior year, the company earned $0.15 earnings per share. The business's quarterly revenue was up 33.6% compared to the same quarter last year. As a group, analysts predict that BioCryst Pharmaceuticals, Inc. will post -2.28 EPS for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing oral medicines for rare and serious diseases. The company uses structure-based drug design and small-molecule research to develop therapies intended to address conditions with limited treatment options.

BioCryst's primary commercial product is Orladeyo (berotralstat), an oral medication used to prevent hereditary angioedema attacks in adults and pediatric patients aged 12 and older. The company also maintains a pipeline of investigational therapies for complement-mediated diseases and other rare disorders, including programs designed to inhibit components of the complement system.

Founded in 1986 and headquartered in Durham, North Carolina, BioCryst has historically conducted research and commercial activities in the United States and worked with international partners to make its products available in additional markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.